A
web-based Atlas of Patient-Derived Xenografts
of cancer patients:A resource of MURAL PDX data
PDX model details
| PDX ID | 426M Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
9 (5*) |
| Average PDX Generation Time (days +/- SEM) | 138 ± 9 |
| Tumor preparation | Tumor solid |
| Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 426M Cx |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 426M Cx | MDM2 | 3.28021 | 19.4299 | gain-high | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 426M Cx | PTEN | -1.00226 | 0.998435 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 426M Cx | SUFU | -1.00226 | 0.998435 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 426M |
|---|---|
| Sample Site | Lung |
| Sample source | Surgery |
| Pathology Tumor Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumor Grade | |
| D'Amico Risk Classification | |
| Tumor Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | PRRT LuTate and Y-Tate, Octreotide |
Patient Information
| Patient Number | 426/452 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | |
| Patient Tumor Collection (Current Model) | |
|---|---|
| Tumour sample ID | 426M |
| Patient Age (binned in 5 year age groups) | 25-29 |
This table displays curated sequence variants
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Gene Symbol | Depth | ALT_FREQ | Consequence | Exon | GnomAD_AF | CADD_PHRED | Clinvar_clnsig | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 426M Cx | DICER1 | 376 | 0.66 | missense_variant | '25/29 | . | 27.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | FOXA1 | 363 | 0.64 | missense_variant | '2/2 | 4.07E-06 | 25.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | BRCA1 | 313 | 0.54 | missense_variant | '7/24 | 0.000264 | 24.7 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | LATS2 | 299 | 0.51 | missense_variant | '8/8 | 4.12E-06 | 25.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | BRCA1 | 375 | 0.51 | missense_variant | '10/24 | 0.0002845 | 0.005 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | BRCA1 | 375 | 0.5 | missense_variant | '10/24 | 0.0002605 | 17.67 | Benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | FOXA2 | 389 | 0.49 | stop_gained | '2/2 | . | 48 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | FOXA2 | 389 | 0.49 | stop_gained | '2/2 | . | 48 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | NCOR1 | 395 | 0.46 | missense_variant | '25/46 | 0.0006336 | 22.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 426M Cx | IRS2 | 515 | 0.27 | inframe_insertion | '1/2 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
This table displays drug response data
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
|---|---|---|---|---|---|---|---|
| 426M Cx | Carboplatin | 50 | qwk | NA | NA | NA | Response |
| 426M Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | No response |
| 426M Cx | Talazoparib | 0.33 | qd | NA | NA | NA | Response |